Reported results
- Total revenues increased 7% to $13.1 billion.
- Growth Portfolio revenues increased 12% to $7.7 billion.
- GAAP EPS was $1.05 and non-GAAP EPS was $1.35.
- Legacy Portfolio revenues of $5.4 billion increased 1%.
- U.S. revenues of $9.1 billion increased 9%.
- International revenues of $4.0 billion increased 3%.
Guidance
- Full-year 2026 revenue guidance range of $49.75 billion to $50.25 billion.
- Full-year 2026 non-GAAP EPS range of $6.35 to $6.55.
- Full-year 2026 other income/(expense) expected to be ~$650 million of expense.
- 2026 Worldwide Eliquis revenue growth guidance of 20% - 25%.
Price and volatility reaction
The stock moved +1.4% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -4.3 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 60.57 | 2026-10-28 |
| Close after release | 61.39 | 2026-10-29 |
| Realised move | +1.4% | close to close |
| 30d ATM IV change | -4.3 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
